Which has better earnings and valuation, SGMT or IMMP?

Prima BioMed has higher revenue and earnings than Sagimet Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sagimet Biosciences $2M 105.56 -$51.04M -$1.34 N/A Prima BioMed $6.69M 8.01 -$39.78M N/A N/A

Is SGMT or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -37.57% -35.52% Prima BioMed N/A N/A N/A

Does the media favor SGMT or IMMP?

In the previous week, Prima BioMed had 13 more articles in the media than Sagimet Biosciences. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.93 beat Prima BioMed's score of 0.10 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, SLGL or IMMP?

Sol-Gel Technologies has higher revenue and earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sol-Gel Technologies $19.39M 10.64 -$6.13M -$0.34 N/A Prima BioMed $6.69M 8.01 -$39.78M N/A N/A

Which has stronger valuation and earnings, IMMP or FHTX?

Prima BioMed has higher earnings, but lower revenue than Foghorn Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.01 -$39.78M N/A N/A Foghorn Therapeutics $30.91M 7.94 -$74.28M -$1.16 N/A

Is IMMP or FHTX more profitable?

Prima BioMed has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Foghorn Therapeutics -266.88% N/A -35.38%

Does the media refer more to IMMP or FHTX?

In the previous week, Prima BioMed had 12 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 15 mentions for Prima BioMed and 3 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.62 beat Prima BioMed's score of 0.10 indicating that Foghorn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Foghorn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, IKT or IMMP?

Prima BioMed has higher revenue and earnings than Inhibikase Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inhibikase Therapeutics $260K 848.04 -$48.26M -$0.43 N/A Prima BioMed $6.69M 8.01 -$39.78M N/A N/A

Is IKT or IMMP more profitable?

Prima BioMed's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Prima BioMed N/A N/A N/A

Which has higher earnings & valuation, IMMP or HELP?

Prima BioMed has higher revenue and earnings than Cybin. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $6.69M 8.01 -$39.78M N/A N/A Cybin N/A N/A -$81.31M -$4.23 N/A

Is IMMP or HELP more profitable?

Prima BioMed's return on equity of 0.00% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Cybin N/A -59.98% -50.80%

Does the media refer more to IMMP or HELP?

In the previous week, Prima BioMed had 13 more articles in the media than Cybin. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Cybin. Cybin's average media sentiment score of 0.93 beat Prima BioMed's score of 0.10 indicating that Cybin is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 14 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cybin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prima BioMed (IMMP) Competitors

$0.36 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$0.36 0.00 (-0.47%)

As of 06/12/2026 07:50 PM Eastern

Compare

IMMP vs. SGMT, SLGL, FHTX, IKT, and HELP

Should you buy Prima BioMed stock or one of its competitors? MarketBeat compares Prima BioMed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Prima BioMed include Sagimet Biosciences (SGMT), Sol-Gel Technologies (SLGL), Foghorn Therapeutics (FHTX), Inhibikase Therapeutics (IKT), and Cybin (HELP). These companies are all part of the "pharmaceutical products" industry.

How does Prima BioMed compare to Sagimet Biosciences?

Sagimet Biosciences (NASDAQ:SGMT) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Prima BioMed had 13 more articles in the media than Sagimet Biosciences. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.93 beat Prima BioMed's score of 0.10 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prima BioMed's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-37.57%	-35.52%
Prima BioMed	N/A	N/A	N/A

Sagimet Biosciences currently has a consensus price target of $25.57, indicating a potential upside of 294.62%. Prima BioMed has a consensus price target of $5.50, indicating a potential upside of 1,412.24%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than Sagimet Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 14.7% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Sagimet Biosciences has a beta of 3.42, meaning that its stock price is 242% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Sagimet Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	105.56	-$51.04M	-$1.34	N/A
Prima BioMed	$6.69M	8.01	-$39.78M	N/A	N/A

Summary

Sagimet Biosciences beats Prima BioMed on 7 of the 13 factors compared between the two stocks.

How does Prima BioMed compare to Sol-Gel Technologies?

Sol-Gel Technologies (NASDAQ:SLGL) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

Sol-Gel Technologies currently has a consensus target price of $110.00, indicating a potential upside of 49.78%. Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,412.24%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Prima BioMed had 13 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Sol-Gel Technologies. Sol-Gel Technologies' average media sentiment score of 0.44 beat Prima BioMed's score of 0.10 indicating that Sol-Gel Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Sol-Gel Technologies	Neutral
Prima BioMed	Neutral

Prima BioMed has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Prima BioMed's return on equity of 0.00% beat Sol-Gel Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%
Prima BioMed	N/A	N/A	N/A

Sol-Gel Technologies has higher revenue and earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sol-Gel Technologies	$19.39M	10.64	-$6.13M	-$0.34	N/A
Prima BioMed	$6.69M	8.01	-$39.78M	N/A	N/A

Sol-Gel Technologies has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market.

Summary

Sol-Gel Technologies beats Prima BioMed on 9 of the 15 factors compared between the two stocks.

How does Prima BioMed compare to Foghorn Therapeutics?

Prima BioMed (NASDAQ:IMMP) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

In the previous week, Prima BioMed had 12 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 15 mentions for Prima BioMed and 3 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 0.62 beat Prima BioMed's score of 0.10 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Foghorn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Prima BioMed has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -266.88%.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Prima BioMed has higher earnings, but lower revenue than Foghorn Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.01	-$39.78M	N/A	N/A
Foghorn Therapeutics	$30.91M	7.94	-$74.28M	-$1.16	N/A

Prima BioMed currently has a consensus price target of $5.50, suggesting a potential upside of 1,412.24%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 173.41%. Given Prima BioMed's higher possible upside, equities research analysts plainly believe Prima BioMed is more favorable than Foghorn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Prima BioMed has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.89, meaning that its stock price is 189% more volatile than the broader market.

Summary

Foghorn Therapeutics beats Prima BioMed on 8 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Prima BioMed (NASDAQ:IMMP) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

In the previous week, Prima BioMed had 13 more articles in the media than Inhibikase Therapeutics. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Inhibikase Therapeutics. Inhibikase Therapeutics' average media sentiment score of 1.44 beat Prima BioMed's score of 0.10 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Positive
Prima BioMed	Neutral

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 7.1% of Inhibikase Therapeutics shares are owned by insiders. Comparatively, 3.1% of Prima BioMed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Prima BioMed's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Prima BioMed	N/A	N/A	N/A

Prima BioMed has higher revenue and earnings than Inhibikase Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A
Prima BioMed	$6.69M	8.01	-$39.78M	N/A	N/A

Inhibikase Therapeutics presently has a consensus price target of $5.40, suggesting a potential upside of 223.35%. Prima BioMed has a consensus price target of $5.50, suggesting a potential upside of 1,412.24%. Given Prima BioMed's higher probable upside, analysts plainly believe Prima BioMed is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Inhibikase Therapeutics has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market.

Summary

Inhibikase Therapeutics and Prima BioMed tied by winning 7 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Cybin?

Prima BioMed (NASDAQ:IMMP) and Cybin (NASDAQ:HELP) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Prima BioMed has higher revenue and earnings than Cybin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$6.69M	8.01	-$39.78M	N/A	N/A
Cybin	N/A	N/A	-$81.31M	-$4.23	N/A

Prima BioMed has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market. Comparatively, Cybin has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

In the previous week, Prima BioMed had 13 more articles in the media than Cybin. MarketBeat recorded 15 mentions for Prima BioMed and 2 mentions for Cybin. Cybin's average media sentiment score of 0.93 beat Prima BioMed's score of 0.10 indicating that Cybin is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cybin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed presently has a consensus target price of $5.50, suggesting a potential upside of 1,412.24%. Cybin has a consensus target price of $58.75, suggesting a potential upside of 1,266.28%. Given Prima BioMed's higher possible upside, analysts plainly believe Prima BioMed is more favorable than Cybin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Prima BioMed's return on equity of 0.00% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Cybin	N/A	-59.98%	-50.80%

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 15.0% of Cybin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Prima BioMed beats Cybin on 7 of the 12 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$53.60M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.00	24.00	24.42
Price / Sales	8.01	303.98	516.42	110.81
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	0.58	8.32	10.74	6.82
Net Income	-$39.78M	$23.94M	$3.57B	$337.56M
7 Day Performance	-1.41%	1.84%	0.58%	1.16%
1 Month Performance	-30.02%	-0.04%	1.48%	3.16%
1 Year Performance	-79.10%	44.82%	25.41%	30.60%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	2.0546 of 5 stars	$0.36 flat	$5.50 +1,412.2%	-79.1%	$53.60M	$6.69M	N/A	2,021
SGMT Sagimet Biosciences	2.9499 of 5 stars	$6.53 -3.4%	$25.57 +291.6%	-21.6%	$220.27M	$2M	N/A	8
SLGL Sol-Gel Technologies	3.0307 of 5 stars	$80.00 +2.6%	$110.00 +37.5%	+876.6%	$219.11M	$19.39M	N/A	50	Short Interest Increase Gap Up
FHTX Foghorn Therapeutics	2.4542 of 5 stars	$3.71 -0.5%	$11.43 +208.0%	-3.2%	$219M	$30.91M	N/A	120	News Coverage Analyst Upgrade Gap Down
IKT Inhibikase Therapeutics	2.4599 of 5 stars	$1.62 -0.6%	$5.50 +239.5%	N/A	$215.21M	$260K	N/A	6	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. SGMT, SLGL, FHTX, IKT, and HELP

How does Prima BioMed compare to Sagimet Biosciences?

Summary

How does Prima BioMed compare to Sol-Gel Technologies?

Summary

How does Prima BioMed compare to Foghorn Therapeutics?

Summary

How does Prima BioMed compare to Inhibikase Therapeutics?

Summary

How does Prima BioMed compare to Cybin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. SGMT, SLGL, FHTX, IKT, and HELP

How does Prima BioMed compare to Sagimet Biosciences?

Does the media favor SGMT or IMMP?

Is SGMT or IMMP more profitable?

Do analysts rate SGMT or IMMP?

Do institutionals & insiders have more ownership in SGMT or IMMP?

Which has more risk and volatility, SGMT or IMMP?

Which has better earnings and valuation, SGMT or IMMP?

Summary

How does Prima BioMed compare to Sol-Gel Technologies?

Do analysts recommend SLGL or IMMP?

Do insiders & institutionals have more ownership in SLGL or IMMP?

Does the media favor SLGL or IMMP?

Is SLGL or IMMP more profitable?

Which has better valuation & earnings, SLGL or IMMP?

Which has more risk and volatility, SLGL or IMMP?

Summary

How does Prima BioMed compare to Foghorn Therapeutics?

Does the media refer more to IMMP or FHTX?

Do institutionals and insiders hold more shares of IMMP or FHTX?

Is IMMP or FHTX more profitable?

Which has stronger valuation and earnings, IMMP or FHTX?

Do analysts recommend IMMP or FHTX?

Which has more volatility and risk, IMMP or FHTX?

Summary

How does Prima BioMed compare to Inhibikase Therapeutics?

Does the media prefer IKT or IMMP?

Do insiders & institutionals hold more shares of IKT or IMMP?

Is IKT or IMMP more profitable?

Which has preferable earnings & valuation, IKT or IMMP?

Do analysts rate IKT or IMMP?

Which has more volatility and risk, IKT or IMMP?

Summary

How does Prima BioMed compare to Cybin?

Which has higher earnings & valuation, IMMP or HELP?

Which has more volatility & risk, IMMP or HELP?

Does the media refer more to IMMP or HELP?

Do analysts rate IMMP or HELP?

Is IMMP or HELP more profitable?

Do insiders and institutionals have more ownership in IMMP or HELP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools